Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells.
|
| Abstract |
Trophoblast cell surface antigen 2 (TROP2) is highly expressed on various epithelial tumors and correlates with poor prognosis. We developed the novel TROP2-directed antibody-drug conjugate (ADC), datopotamab deruxtecan (Dato-DXd, DS-1062a), with a potent DNA topoisomerase I inhibitor (DXd), and evaluated its antitumor activity and safety profiles in preclinical models.The pharmacologic activity and mechanism of action of Dato-DXd were investigated in several human cancer cell lines and xenograft mouse models including patient-derived xenograft (PDX) models. Safety profiles were also assessed in rats and cynomolgus monkeys.Dato-DXd bound specifically to TROP2 and was internalized into tumor cells followed by intracellular trafficking to lysosome and DXd release, which induced DNA damage and apoptosis in TROP2-expressing tumor cells in vitro. Dato-DXd exhibited in vivo antitumor activity with DNA damage induced by the accumulated DXd in TROP2-expressing xenograft tumors, but neither isotype control IgG-ADC nor anti-TROP2 antibody had this effect. Dato-DXd also showed potent antitumor activity with tumor regression in several TROP2-expressing xenograft tumors including NSCLC PDX models. Safety profiles of Dato-DXd in rats and cynomolgus monkeys were acceptable.Dato-DXd demonstrated potent antitumor activity against TROP2-expressing tumors by efficient payload delivery into tumors and acceptable safety profiles in preclinical models. These results suggest Dato-DXd could be a valuable treatment option for patients with TROP2-expressing tumors in the clinical setting.
|
|---|---|
| Authors | Daisuke Okajima, Satoru Yasuda, Takanori Maejima, Tsuyoshi Karibe, Ken Sakurai, Tetsuo Aida, Tadashi Toki, Junko Yamaguchi, Michiko Kitamura, Reiko Kamei, Tomomichi Fujitani, Tomoyo Honda, Tomoko Shibutani, Sumie Muramatsu, Takashi Nakada, Riki Goto, Shu Takahashi, Miki Yamaguchi, Hirofumi Hamada, Yutaka Noguchi, Masato Murakami, Yuki Abe, Toshinori Agatsuma |
| Journal | Molecular cancer therapeutics (Mol Cancer Ther) Vol. 20 Issue 12 Pg. 2329-2340 (12 2021) ISSN: 1538-8514 [Electronic] United States |
| PMID | 34413126 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't) |
| Copyright | ©2021 The Authors; Published by the American Association for Cancer Research. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!